JP2022516075A5 - - Google Patents

Info

Publication number
JP2022516075A5
JP2022516075A5 JP2021537087A JP2021537087A JP2022516075A5 JP 2022516075 A5 JP2022516075 A5 JP 2022516075A5 JP 2021537087 A JP2021537087 A JP 2021537087A JP 2021537087 A JP2021537087 A JP 2021537087A JP 2022516075 A5 JP2022516075 A5 JP 2022516075A5
Authority
JP
Japan
Prior art keywords
compound according
groups
composition
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021537087A
Other languages
English (en)
Japanese (ja)
Other versions
JP7547345B2 (ja
JP2022516075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068597 external-priority patent/WO2020139960A1/en
Publication of JP2022516075A publication Critical patent/JP2022516075A/ja
Publication of JP2022516075A5 publication Critical patent/JP2022516075A5/ja
Application granted granted Critical
Publication of JP7547345B2 publication Critical patent/JP7547345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021537087A 2018-12-27 2019-12-26 ガレクチン-3阻害性c-グリコシド Active JP7547345B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862785588P 2018-12-27 2018-12-27
US62/785,588 2018-12-27
US201962927192P 2019-10-29 2019-10-29
US62/927,192 2019-10-29
PCT/US2019/068597 WO2020139960A1 (en) 2018-12-27 2019-12-26 Galectin-3 inhibiting c-glycosides

Publications (3)

Publication Number Publication Date
JP2022516075A JP2022516075A (ja) 2022-02-24
JP2022516075A5 true JP2022516075A5 (cg-RX-API-DMAC7.html) 2022-12-27
JP7547345B2 JP7547345B2 (ja) 2024-09-09

Family

ID=69191291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537087A Active JP7547345B2 (ja) 2018-12-27 2019-12-26 ガレクチン-3阻害性c-グリコシド

Country Status (9)

Country Link
US (1) US11873317B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902797A1 (cg-RX-API-DMAC7.html)
JP (1) JP7547345B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210110645A (cg-RX-API-DMAC7.html)
CN (2) CN113490665B (cg-RX-API-DMAC7.html)
AU (1) AU2019416330A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021012482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122321A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020139960A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7547345B2 (ja) 2018-12-27 2024-09-09 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN115244045A (zh) * 2019-12-24 2022-10-25 糖模拟物有限公司 抑制半乳凝素-3的c-糖苷酮、醚和醇
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2022073969A1 (en) * 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) * 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
WO2022241183A1 (en) 2021-05-14 2022-11-17 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2022250976A1 (en) * 2021-05-28 2022-12-01 Glycomimetics, Inc. Galectin-3 inhibiting c-glycoside oximes
WO2024220435A1 (en) * 2023-04-18 2024-10-24 Truebinding, Inc. Methods of treating eye disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK455088D0 (da) 1988-08-12 1988-08-12 Symbicom Ab Syntetiske receptoranaloger
CA2106301C (en) 1991-03-18 1999-04-06 Chi-Huey Wong Oligosaccharide enzyme substrates and inhibitors: method and compositions
US5620864A (en) 1992-06-29 1997-04-15 Health Research, Inc. Acceptor for fucosyl transferase
DK76193D0 (da) 1993-06-25 1993-06-25 Astra Ab Kulhydratderivater
DE19643764A1 (de) 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (20-0-Verknüpfung)
DE19654180A1 (de) 1996-12-23 1998-06-25 Hoechst Ag Phosphane, Verfahren zu ihrer Herstellung und ihre Verwendung in Metallkomplexen
US6323176B1 (en) 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
WO2000035945A1 (en) 1998-12-16 2000-06-22 Eli Lilly And Company Cyclic peptide antifungal agents having a sugar substituent
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
FR2835527B1 (fr) 2002-02-05 2004-03-12 Centre Nat Rech Scient Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et des desordres metaboliques caracterises par une resistance a l'insuline
AUPS213802A0 (en) 2002-05-03 2002-06-06 Alchemia Pty Ltd Disaccharides for drug discovery
CA2528152A1 (en) 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2005061523A1 (en) 2003-12-23 2005-07-07 Progen Industries Limited Glycosaminoglycan (gag) mimetics
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
EP1632498A1 (en) 2004-09-03 2006-03-08 Syngenta Participations AG Derivatives of avermectin, avermectin monosaccharide and avermectin aglycone
WO2007021721A2 (en) 2005-08-09 2007-02-22 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
US20090214439A1 (en) 2006-03-15 2009-08-27 Trustees Of Tufts College Fluorinated Carbohydrates and Their Use in Tumor Visualization, Tissue Engineering, and Cancer Chemotherapy
US20090176717A1 (en) 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
EP1964846A1 (en) 2007-02-27 2008-09-03 Bracco Imaging, S.P.A. Process for the preparation of contrast agents
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
KR102085687B1 (ko) 2008-04-08 2020-03-06 슬로안-케테링인스티튜트퍼캔서리서치 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
US8697862B2 (en) 2008-05-16 2014-04-15 Galecto Biotech Ab Synthesis of galactoside inhibitors
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
ES2652488T3 (es) 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
WO2011002673A1 (en) 2009-07-01 2011-01-06 Temple University - Of The Commonwealth System Of Higher Education Leptin agonist and methods of use
US9624255B2 (en) 2009-08-11 2017-04-18 Arizona Board Of Regents Carbohydrate-mediated tumor targeting
WO2011129314A1 (ja) 2010-04-13 2011-10-20 和光純薬工業株式会社 糖類の重水素化方法
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
WO2013170985A1 (en) 2012-05-18 2013-11-21 Boettger Erik C New aminoglycoside antibiotics targeting bacterial 16s ribosomal rna lacking ototoxicity
EP2859112A4 (en) 2012-06-08 2015-10-28 Glycom As PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDES AND OLIGOSACCHARIDE GLYCOSIDES BY FERMENTATION
GB201214736D0 (en) 2012-08-17 2012-10-03 Isis Innovation Inflammation imaging and therapy
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
IN2015DN02573A (cg-RX-API-DMAC7.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
GB2511137A (en) 2013-02-26 2014-08-27 Glykos Finland Oy Chelator Molecule
AU2014236356A1 (en) 2013-03-14 2015-09-24 The Regents Of The University Of California Thiosaccharide mucolytic agents
DK2991683T3 (da) 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
US20170095496A1 (en) 2014-04-08 2017-04-06 Galecto Biotech Ab Galactoside inhibitors for new uses
FR3020952B1 (fr) 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
WO2015197082A1 (en) 2014-06-27 2015-12-30 Glycom A/S Oligosaccharide production
JP6735680B2 (ja) 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
US20170274087A1 (en) 2014-09-19 2017-09-28 Emory University Saccharide analogs and agents for the diagnosis and therapy of bacterial infections
WO2016113335A1 (en) 2015-01-16 2016-07-21 Galecto Biotech Ab Novel galactoside inhibitor of galectins
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US11406655B2 (en) 2015-05-12 2022-08-09 Galecto Biotech Ab Once-daily treatment of pulmonary fibrosis
US10799522B2 (en) 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7547345B2 (ja) 2018-12-27 2024-09-09 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3136661A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
WO2021086816A1 (en) 2019-10-29 2021-05-06 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides

Similar Documents

Publication Publication Date Title
JP2022507065A5 (cg-RX-API-DMAC7.html)
JP4860474B2 (ja) Pdgfrによって仲介される病気のためのジアリール尿素
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
TWI335919B (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2022505525A5 (cg-RX-API-DMAC7.html)
JP2024521706A5 (cg-RX-API-DMAC7.html)
JP2020528889A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
WO2015138902A1 (en) Combination therapy with glutaminase inhibitors
TW201625527A (zh) 苯并雜環化合物及其應用
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
RU2007114293A (ru) Диаминотриазольные соединения, применяемые в качестве ингибиторов протеиновой киназы
RU2008134534A (ru) 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов
JP2008510770A5 (cg-RX-API-DMAC7.html)
UA128160C2 (uk) Сполуки, що інгібують rip1, а також способи їх одержання та застосування
RU2020102453A (ru) Фармацевтические композиции
JP2008506644A5 (cg-RX-API-DMAC7.html)
EA036001B1 (ru) Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
HUP0304082A2 (hu) 4-Amino-5-fenil-7-ciklobutil-pirrolo[2,3-d]pirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CA2916097A1 (en) Substituted benzylpyrazoles
CA2422380A1 (en) Pyrazole compounds useful as protein kinase inhibitors
JP2018524403A5 (cg-RX-API-DMAC7.html)
CA2609389A1 (en) Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
JP2006512339A5 (cg-RX-API-DMAC7.html)